{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:31:49Z","timestamp":1756571509980,"version":"3.37.3"},"reference-count":262,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024087","name":"Theramex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.reumae.2024.09.002","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:17:29Z","timestamp":1727439449000},"page":"423-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis"],"prefix":"10.1016","volume":"20","author":[{"given":"Jos\u00e9 Mar\u00eda","family":"\u00c1lvaro-Gracia \u00c1lvaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"D\u00edaz del Campo Fontecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Andr\u00e9u S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa Criado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"C\u00e1liz C\u00e1liz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Castrej\u00f3n Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e8ctor","family":"Corominas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"G\u00f3mez Puerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Manrique Arija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Mena V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ortiz Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chamaida","family":"Plasencia Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Silva Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Tornero Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2024.09.002_bib0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.reuma.2015.05.001","article-title":"2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis","volume":"11","author":"Sanmart\u00ed","year":"2015","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2024.09.002_bib0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"year":"2019","series-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Manejo de Pacientes con Artritis Reumatoide","key":"10.1016\/j.reumae.2024.09.002_bib0020"},{"unstructured":"OCfE-bM. Centre for evidence based medicine \u2014 levels of evidence (March 2009). Available from: http:\/\/www.cebm.net\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/.","key":"10.1016\/j.reumae.2024.09.002_bib0025"},{"key":"10.1016\/j.reumae.2024.09.002_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0035","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","article-title":"What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review","volume":"73","author":"Van Nies","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0040","doi-asserted-by":"crossref","first-page":"e000870","DOI":"10.1136\/rmdopen-2018-000870","article-title":"Window of opportunity in rheumatoid arthritis \u2014 definitions and supporting evidence: from old to new perspectives","volume":"5","author":"Burgers","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2024.09.002_bib0045","doi-asserted-by":"crossref","first-page":"e000323","DOI":"10.1136\/rmdopen-2016-000323","article-title":"Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials","volume":"2","author":"Emamikia","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2024.09.002_bib0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","article-title":"Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial","volume":"388","author":"Bijlsma","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0055","first-page":"25","article-title":"Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study","volume":"80","author":"Allaart","year":"2007","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.reumae.2024.09.002_bib0060","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib0065","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kep261","article-title":"Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial","volume":"48","author":"Soubrier","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0070","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","article-title":"2016 update of the EULAR recommendations for the management of early arthritis","volume":"76","author":"Combe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s41927-020-00127-6","article-title":"First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study","volume":"4","author":"Muilu","year":"2020","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0080","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1093\/rheumatology\/keab880","article-title":"Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort","volume":"61","author":"Verstappen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0090","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2012-203165","article-title":"Drug therapy in undifferentiated arthritis: a systematic literature review","volume":"72","author":"Wevers-de Boer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0095","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-019-0279-6","article-title":"Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets","volume":"15","author":"Aletaha","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0105","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/ar4491","article-title":"Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs","volume":"16","author":"Radner","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0110","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1136\/annrheumdis-2013-204906","article-title":"Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes","volume":"74","author":"Ruyssen-Witrand","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0115","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1136\/annrheumdis-2015-208669","article-title":"Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds","volume":"75","author":"Nikiphorou","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2024.09.002_bib0120","series-title":"Programme Grants for Applied Research","article-title":"Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme","author":"Scott","year":"2021"},{"key":"10.1016\/j.reumae.2024.09.002_bib0125","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0135","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0140","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/ard.2004.030924","article-title":"Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial","volume":"64","author":"Fransen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0145","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/annrheumdis-2013-204588","article-title":"Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Gaujoux-Viala","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0150","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial","volume":"383","author":"Smolen","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0160","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1136\/annrheumdis-2013-203229","article-title":"Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study","volume":"73","author":"Combe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0165","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib0170","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1186\/ar4361","article-title":"Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study","volume":"15","author":"Heimans","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0175","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/annrheumdis-2013-203243","article-title":"A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study","volume":"73","author":"Heimans","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0180","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2012-202735","volume":"73","author":"H\u00f8rslev-Petersen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0185","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2012-201365","article-title":"Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo study)","volume":"72","author":"Leirisalo-Repo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0195","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/annrheumdis-2013-204882","article-title":"A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0200","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","article-title":"Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0205","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/art.24367","article-title":"Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis","volume":"61","author":"van der Kooij","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib0210","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/rheumatology\/ker355","article-title":"Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial","volume":"51","author":"van Eijk","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0215","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/ard.2008.092254","article-title":"Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis","volume":"68","author":"Van der Kooij","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0220","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41584-020-0461-x","article-title":"Digital health technologies: opportunities and challenges in rheumatology","volume":"16","author":"Solomon","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0225","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2022-222341","article-title":"2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases","volume":"81","author":"de Thurah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0230","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/acr.23153","article-title":"Telerheumatology: a systematic review","volume":"69","author":"McDougall","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0235","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12891-016-1002-2","article-title":"Effectiveness of a telemonitoring intensive strategy in early rheumatoid arthritis: comparison with the conventional management approach","volume":"17","author":"Salaffi","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.reumae.2024.09.002_bib0240","doi-asserted-by":"crossref","first-page":"e14730","DOI":"10.2196\/14730","article-title":"Mobile health apps for self-management of rheumatic and musculoskeletal diseases: systematic literature review","volume":"7","author":"Najm","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.reumae.2024.09.002_bib0245","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/acr.24253","article-title":"Real-world outcomes associated with methotrexate, sulfasalazine, and hydroxychloroquine triple therapy versus tumor necrosis factor inhibitor\/methotrexate combination therapy in patients with rheumatoid arthritis","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0250","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/acr.23759","article-title":"Low persistence rates in patients with rheumatoid arthritis treated with triple therapy and adverse drug events associated with sulfasalazine","volume":"71","author":"Erhardt","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0255","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(12)60027-0","article-title":"Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial","volume":"379","author":"Van Vollenhoven","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0260","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/art.38012","article-title":"Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial","volume":"65","author":"O\u2019Dell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib0265","first-page":"S46","article-title":"Optimal administration and dosage of methotrexate","volume":"28 5 Suppl 61","author":"Braun","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0270","doi-asserted-by":"crossref","first-page":"e0221823","DOI":"10.1371\/journal.pone.0221823","article-title":"Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis","volume":"14","author":"Bujor","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.reumae.2024.09.002_bib0275","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.reuma.2015.05.001","article-title":"Actualizaci\u00f3n 2014 del Documento de Consenso de la Sociedad Espa\u00f1ola de Reumatolog\u00eda sobre el uso de terapias biol\u00f3gicas en la artritis reumatoide","volume":"11","author":"Sanmart\u00ed","year":"2015","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2024.09.002_bib0280","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/ard.2008.099861","article-title":"Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis","volume":"68","author":"Katchamart","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0285","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/BOR.0b013e32834456bf","article-title":"Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action","volume":"23","author":"Katz","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0290","first-page":"CD000959","article-title":"Antimalarials for treating rheumatoid arthritis","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.reumae.2024.09.002_bib0295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","article-title":"Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"43","author":"Sharp","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib0300","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0305","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.2006.066761","article-title":"Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial","volume":"66","author":"Burmester","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0310","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","article-title":"Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide","volume":"68","author":"Strangfeld","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0315","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1093\/rheumatology\/keac240","article-title":"Leflunomide in combination with JAK inhibitors in the treatment of rheumatoid arthritis: a case series","volume":"61","author":"Kvacskay","year":"2022","journal-title":"Rheumatology (Oxford)"},{"year":"2011","series-title":"Proyecto EMAR II. Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en Espa\u00f1a. Informe de resultados","key":"10.1016\/j.reumae.2024.09.002_bib0320"},{"key":"10.1016\/j.reumae.2024.09.002_bib0325","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.35","article-title":"Clinical efficacy of sulphasalazine \u2014 a review","volume":"34 Suppl 2","author":"Capell","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0330","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis","volume":"1","author":"Van der Heijde","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0335","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.40","article-title":"Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis","volume":"34 Suppl 2","author":"Van Riel","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0345","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0350","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/bmj.287.6399.1099","article-title":"Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial","volume":"287","author":"Neumann","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0355","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar2561","article-title":"Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort","volume":"10","author":"Gonz\u00e1lez-Alvaro","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0360","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00296-010-1643-7","article-title":"The treatment of rheumatoid arthritis during pregnancy","volume":"31","author":"Partlett","year":"2011","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.reumae.2024.09.002_bib0365","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1592\/phco.22.13.1157.33525","article-title":"A review of methotrexate-induced accelerated nodulosis","volume":"22","author":"Patatanian","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.reumae.2024.09.002_bib0370","article-title":"NORD-STAR Study Group. A multicenter randomized study in early rheumatoid arthritis to compare active conventional therapy versus three biological treatments: 24 week efficacy and safety results of the NORD-STAR Trial [abstract]","volume":"71 Suppl 10","author":"Lund Hetland","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0375","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0380","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.21037\/apm-21-1485","article-title":"A systematic review and meta-analysis: effects of glucocorticoids on rheumatoid arthritis and systemic lupus erythematosus","volume":"10","author":"Sun","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0385","doi-asserted-by":"crossref","first-page":"918356","DOI":"10.3389\/fendo.2022.918356","article-title":"High mortality rate in oral glucocorticoid users: a population-based matched cohort study","volume":"13","author":"Einarsdottir","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0390","doi-asserted-by":"crossref","first-page":"15844","DOI":"10.1038\/s41598-022-20016-x","article-title":"The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis","volume":"12","author":"Moshayedi","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.reumae.2024.09.002_bib0395","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0400","first-page":"ii3","article-title":"Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies","volume":"55 Suppl 2","author":"Billsma","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0405","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib0410","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0415","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/ard.2009.121160","article-title":"A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study","volume":"69","author":"Visser","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0420","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib0425","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0430","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0435","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0440","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0445","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0450","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"Van der Heijde","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2024.09.002_bib0455","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"Van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0460","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0465","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0470","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0475","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0480","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0485","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0490","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0495","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0500","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0505","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0510","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0515","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0520","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.reumae.2024.09.002_bib0525","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0530","article-title":"Monotherapy with upadacitinib in MTX-na\u00efve patients with rheumatoid arthritis: results at 48 weeks [abstract]","volume":"71 Suppl 10","author":"Van Vollenhoven","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0535","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"year":"2023","series-title":"Janus kinase inhibitors (JAKi)","key":"10.1016\/j.reumae.2024.09.002_bib0540"},{"key":"10.1016\/j.reumae.2024.09.002_bib0545","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O\u2019Dell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib0550","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/ard.2007.085696","article-title":"The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study","volume":"68","author":"Finckh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0555","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10067-009-1349-y","article-title":"Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha","volume":"29","author":"De Stefano","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0560","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/art.21830","volume":"54","author":"Hyrich","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib0565","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3899\/jrheum.151014","article-title":"Effectiveness of tumor necrosis factor inhibitors in combination with various csDMARD in the treatment of rheumatoid arthritis: data from the DREAM registry","volume":"43","author":"Manders","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0570","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/annrheumdis-2011-200003","article-title":"Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration","volume":"71","author":"Chatzidionysiou","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0575","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/acr.22327","article-title":"Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register","volume":"66","author":"Richter","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0580","doi-asserted-by":"crossref","first-page":"e0123392","DOI":"10.1371\/journal.pone.0123392","article-title":"Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis","volume":"10","author":"Narv\u00e1ez","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.reumae.2024.09.002_bib0585","article-title":"Should we prefer leflunomide to methotrexate in combination with biologics? A systematic review and a meta-analysis [abstract]","volume":"70 Suppl 9","author":"Decarriere","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0590","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/annrheumdis-2016-209383","article-title":"Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review","volume":"75","author":"Dur\u00e1n","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0595","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0600","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.151009","article-title":"Methotrexate dosage reduction upon adalimumab initiation: clinical and ultrasonographic outcomes from the randomized noninferiority MUSICA trial","volume":"43","author":"Kaeley","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0605","first-page":"485","article-title":"Real-world experience with tofacitinib for the treatment of rheumatoid arthritis","volume":"37","author":"Caporali","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0610","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/1756-185X.12910","article-title":"Oral Methotrexate in split dose weekly versus oral or parenteral methotrexate once weekly in rheumatoid arthritis: a short-term study","volume":"21","author":"Dhaon","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0615","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.reumae.2024.09.002_bib0620","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0625","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0630","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2024.09.002_bib0635","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0640","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0645","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0650","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s12325-018-0757-2","article-title":"Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review","volume":"35","author":"Emery","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0655","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2014-205752","article-title":"Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study","volume":"74","author":"Huizinga","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0660","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","article-title":"Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0665","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13075-017-1410-1","article-title":"Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"19","author":"Schiff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0670","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0675","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1093\/rheumatology\/keac048","article-title":"Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia","volume":"61","author":"Fletcher","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0680","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","article-title":"Drug retention of 7 biologics and tofacitinib in biologics-na\u00efve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study","volume":"22","author":"Ebina","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0685","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/CEOR.S115706","article-title":"Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication","volume":"8","author":"Bonafede","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.reumae.2024.09.002_bib0690","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/14397595.2018.1537556","article-title":"Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan","volume":"29","author":"Kondo","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0695","first-page":"400","article-title":"Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany","volume":"31","author":"Beresniak","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0700","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40744-020-00201-y","article-title":"Real-world persistence with tocilizumab compared to other subcutaneous biologic disease-modifying antirheumatic drugs among patients with rheumatoid arthritis switching from another biologic","volume":"7","author":"Best","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0705","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3899\/jrheum.101324","article-title":"Effectiveness of a third tumor necrosis factor-\u03b1-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis","volume":"38","author":"Blom","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0710","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211060910","article-title":"Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study","volume":"13","author":"Bogas","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0715","first-page":"1","article-title":"Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT","volume":"22","author":"Brown","year":"2018","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.reumae.2024.09.002_bib0720","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","article-title":"Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis","volume":"20","author":"Chastek","year":"2017","journal-title":"J Med Econ"},{"key":"10.1016\/j.reumae.2024.09.002_bib0725","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1007\/s12325-017-0617-5","article-title":"Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA","volume":"34","author":"Chastek","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0730","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/03009742.2012.729607","article-title":"Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort","volume":"42","author":"Chatzidionysiou","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0735","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.semarthrit.2021.06.002","article-title":"Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: cohort study in a real world setting","volume":"51","author":"Choi","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib0740","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13075-019-1917-8","article-title":"Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata\u00ae clinical database and registry","volume":"21","author":"Choquette","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0745","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0750","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0755","doi-asserted-by":"crossref","first-page":"e001174","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2024.09.002_bib0760","first-page":"1039","article-title":"Effectiveness and costs among rheumatoid arthritis patients treated with targeted immunomodulators using real-world U.S. data","volume":"26","author":"Gharaibeh","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.reumae.2024.09.002_bib0765","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.reumae.2024.09.002_bib0770","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2024.09.002_bib0775","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0780","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/acr.24358","article-title":"Treatment sequences after discontinuing a tumor necrosis factor inhibitor in patients with rheumatoid arthritis: a comparison of cycling versus swapping strategies","volume":"73","author":"Karpes Matusevich","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0785","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/03007995.2020.1846172","article-title":"Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis","volume":"37","author":"Lopatina","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.reumae.2024.09.002_bib0790","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-015-0630-5","article-title":"Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial","volume":"17","author":"Manders","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0795","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/03007995.2019.1688271","article-title":"Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea","volume":"36","author":"Park","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.reumae.2024.09.002_bib0800","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib0805","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14397595.2018.1447264","article-title":"Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data","volume":"29","author":"Takabayashi","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0810","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10067-015-2879-0","article-title":"Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice","volume":"34","author":"Backhaus","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0815","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s10067-019-04508-2","article-title":"Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis","volume":"38","author":"Elmedany","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0820","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","article-title":"Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies","volume":"53","author":"Favalli","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0825","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez120","article-title":"Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register","author":"Frisell","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0830","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/annrheumdis-2013-203936","article-title":"The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor","volume":"74","author":"Harrold","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0835","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-015-0776-1","article-title":"Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry","volume":"17","author":"Harrold","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0840","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10067-014-2711-2","article-title":"Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies","volume":"33","author":"Hirabara","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0845","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/annrheumdis-2017-212845","volume":"77","author":"Lauper","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0850","first-page":"103","article-title":"Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor","volume":"44","author":"Santos-Faria","year":"2019","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.reumae.2024.09.002_bib0855","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/jcpt.13380","volume":"46","author":"Sung","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0860","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.reuma.2015.11.019","article-title":"VARIAR study: assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist","volume":"12","author":"Torrente-Segarra","year":"2016","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2024.09.002_bib0865","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.clinthera.2016.11.004","article-title":"Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis","volume":"38","author":"Vieira","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0870","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s12325-017-0578-8","volume":"34","author":"Wei","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib0875","article-title":"Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"Roodenrijs","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2024.09.002_bib0880","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/annrheumdis-2012-201324","article-title":"Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR study","volume":"71","author":"Gomez-Reino","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0885","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keac285","article-title":"Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy","volume":"62","author":"Amstad","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0890","first-page":"192","article-title":"Treatment persistence and healthcare costs among patients with rheumatoid arthritis after a change in targeted therapy","volume":"11","author":"Bonafede","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.reumae.2024.09.002_bib0895","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/annrheumdis-2013-204417","article-title":"Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy","volume":"73","author":"Das","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0900","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1007\/s10067-020-05015-5","article-title":"Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis \u2014 the ANSWER cohort study","volume":"39","author":"Ebina","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0905","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","article-title":"Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway","volume":"60","author":"Fitton","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0910","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/1756-185X.12845","article-title":"Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study","volume":"19","author":"Pascart","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0915","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard-2022-222835","article-title":"After JAK inhibitor failure: to cycle or to switch, that is the question \u2014 data from the JAK-pot collaboration of registries","volume":"82","author":"Pombo-Suarez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0920","doi-asserted-by":"crossref","first-page":"453","DOI":"10.55563\/clinexprheumatol\/cbanza","article-title":"Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: an observational study","volume":"39","author":"Retuerto","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0925","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1007\/s10067-021-05734-3","article-title":"Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry","volume":"40","author":"Sebastiani","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0930","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jbspin.2008.11.009","article-title":"Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis","volume":"76","author":"Brocq","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.reumae.2024.09.002_bib0935","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3109\/s10165-011-0586-5","article-title":"Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity","volume":"22","author":"Harigai","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0940","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3109\/s10165-008-0089-1","article-title":"Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission","volume":"18","author":"Nawata","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0945","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","article-title":"Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study","volume":"74","author":"Tanaka","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0950","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2024.09.002_bib0955","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1136\/annrheumdis-2011-200945","article-title":"Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study","volume":"71","author":"Van der Maas","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0960","doi-asserted-by":"crossref","first-page":"e0270391","DOI":"10.1371\/journal.pone.0270391","article-title":"Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: a prospective cohort study","volume":"17","author":"Mori","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.reumae.2024.09.002_bib0965","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/annrheumdis-2016-209233","article-title":"Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative","volume":"75","author":"Baillet","year":"2016","journal-title":"Ann Rheum Dis"},{"doi-asserted-by":"crossref","unstructured":"Van Vollenhoven R.F., Ostergaard M., Leirisalo-Repo M., Uhlig T., Jansson M., Klackenberg A., et al. In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-armed, double-blind clinical trial. Meeting: 2012 ACR\/ARHP. Annual Meeting. Abstract oral session.","key":"10.1016\/j.reumae.2024.09.002_bib0970","DOI":"10.1136\/annrheumdis-2013-eular.1312"},{"key":"10.1016\/j.reumae.2024.09.002_bib0975","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/art.40196","article-title":"A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis","volume":"69","author":"Weinblatt","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0980","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","article-title":"Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis","volume":"75","author":"van Vollenhoven","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib0985","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/kev298","article-title":"Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up","volume":"55","author":"Chen","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib0990","first-page":"655","article-title":"Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity","volume":"34","author":"Plasencia","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib0995","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial","volume":"350","author":"Van Herwaarden","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2024.09.002_bib1000","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/annrheumdis-2014-206149","article-title":"Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis","volume":"74","author":"Westhovens","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib1005","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2024.09.002_bib1010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","article-title":"Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study","volume":"75","author":"Haschka","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib1015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.reuma.2013.04.012","article-title":"Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions","volume":"10","author":"Inciarte-Mundo","year":"2014","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2024.09.002_bib1020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13075-022-02826-6","article-title":"Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study","volume":"24","author":"Bertsias","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib1025","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00296-017-3749-7","article-title":"Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access","volume":"37","author":"Pavelka","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2024.09.002_bib1030","first-page":"1023","article-title":"Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study","volume":"79","author":"Emery","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib1035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/03009742.2021.1955467","article-title":"Tapering of etanercept is feasible in patients with rheumatoid arthritis in sustained remission: a pragmatic randomized controlled trial","volume":"51","author":"Bertrand","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1040","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00296-020-04651-z","article-title":"Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis","volume":"40","author":"Vasconcelos","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2024.09.002_bib1045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/ijr.14.27","article-title":"Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central\/eastern Europe, Latin America and Asia","volume":"9","author":"Pavelka","year":"2014","journal-title":"Int J Clin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13075-020-02165-4","article-title":"Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort","volume":"22","author":"Dierckx","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib1055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/rheumatology\/keab343","article-title":"Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors","volume":"61","author":"Arnold","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/rheumatology\/key244","article-title":"Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care \u2014 2-year outcomes and predictors","volume":"58","author":"Brahe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.reuma.2018.08.002","article-title":"Biological dose tapering in daily clinical practice: a 10 year follow-up study","volume":"16 5 Pt 1","author":"Alperi-L\u00f3pez","year":"2020","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1070","article-title":"Low-dose rituximab protocol in rheumatoid arthritis-outcome and economic impact","volume":"5","author":"Chandramohan","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.reumae.2024.09.002_bib1075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/08916934.2022.2067985","article-title":"Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases","volume":"55","author":"Lamberg","year":"2022","journal-title":"Autoimmunity"},{"key":"10.1016\/j.reumae.2024.09.002_bib1080","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/rheumatology\/kez470","article-title":"An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs","volume":"59","author":"Pope","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reumae.2024.09.002_bib1085","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/14397595.2019.1641934","article-title":"Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: an interventional study","volume":"30","author":"Asai","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1090","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","article-title":"Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study","volume":"78","author":"Van Mulligen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib1095","first-page":"1513","article-title":"Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis","volume":"35","author":"Mori","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1100","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00296-004-0472-y","article-title":"Pulmonary involvement in rheumatoid arthritis","volume":"25","author":"Bilgici","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2024.09.002_bib1105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.reuma.2022.03.005","article-title":"SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: treatment","volume":"18","author":"Narv\u00e1ez","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1110","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/rheumatology\/key207","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1115","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1120","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib1125","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/biomedicines10071480","article-title":"Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease","volume":"10","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.reumae.2024.09.002_bib1130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib1135","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/jrheum.120906","article-title":"Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1140","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/rheumatology\/keaa160","article-title":"Comment on: Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry: reply","volume":"59","author":"Vadillo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1145","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.reumae.2024.09.002_bib1150","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","article-title":"Non-infectious pulmonary complications of newer biological agents for rheumatic diseases \u2014 a systematic literature review","volume":"50","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib1160","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.reumae.2024.09.002_bib1165","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1097\/RHU.0000000000001552","article-title":"Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients: post hoc analysis from 21 clinical trials","volume":"27","author":"Citera","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1170","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40744-021-00332-w","article-title":"Baricitinib and the risk of incident interstitial lung disease: a descriptive clinical case report from clinical trials","volume":"8","author":"Salvarani","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib1175","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","article-title":"The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis","volume":"55","author":"Silva-Fern\u00e1ndez","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1180","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib1185","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/annrheumdis-2017-212086","article-title":"Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study","volume":"77","author":"Dreyer","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib1190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/M17-2812","article-title":"Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study","volume":"169","author":"Raaschou","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib1195","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S2468-1253(19)30362-0","article-title":"Anti-tumour necrosis factor-\u03b1 therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study","volume":"5","author":"Waljee","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1200","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/rheumatology\/kez475","article-title":"A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy","volume":"59","author":"Xie","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1205","doi-asserted-by":"crossref","first-page":"e0143286","DOI":"10.1371\/journal.pone.0143286","article-title":"Tumor necrosis factor inhibition and head and neck cancer recurrence and death in rheumatoid arthritis","volume":"10","author":"Phillips","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.reumae.2024.09.002_bib1210","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/art.39738","article-title":"Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study","volume":"68","author":"Mamtani","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1215","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/annrheumdis-2014-205745","article-title":"TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study","volume":"74","author":"Raaschou","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib1220","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2024.09.002_bib1225","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.semarthrit.2020.08.007","article-title":"Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies","volume":"50","author":"Xie","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2024.09.002_bib1230","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1235","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.reumae.2024.09.002_bib1240","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13317-021-00153-5","article-title":"Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solipuram","year":"2021","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.reumae.2024.09.002_bib1245","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib1250","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3352","article-title":"Treating rheumatic patients with a malignancy","volume":"13","author":"Elandt","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2024.09.002_bib1255","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-5273(02)00470-9","article-title":"How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH","volume":"86","author":"Anker","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1260","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1388-9842(02)00121-6","article-title":"Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH","volume":"4","author":"Coletta","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.reumae.2024.09.002_bib1265","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.reumae.2024.09.002_bib1270","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"unstructured":"European Medicines Agency: humira (adalimubab). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_es.pdf.","key":"10.1016\/j.reumae.2024.09.002_bib1275"},{"unstructured":"European Medicines Agency: remicade (infliximab). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_es.pdf.","key":"10.1016\/j.reumae.2024.09.002_bib1280"},{"unstructured":"European Medicines Agency: MabThera (rituximab). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera430.","key":"10.1016\/j.reumae.2024.09.002_bib1285"},{"key":"10.1016\/j.reumae.2024.09.002_bib1290","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s00415-012-6790-1","article-title":"Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis","volume":"260","author":"Dobson","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.reumae.2024.09.002_bib1295","doi-asserted-by":"crossref","first-page":"e992","DOI":"10.1212\/NXI.0000000000000992","article-title":"Demyelinating Events Following Initiation of Anti-TNF\u03b1 Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis","volume":"8","author":"Taylor","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.reumae.2024.09.002_bib1300","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/annrheumdis-2015-208490","article-title":"Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry","volume":"75","author":"Dreyer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2024.09.002_bib1305","first-page":"e558","article-title":"Risk of multiple sclerosis among users of antitumor necrosis factor \u03b1 in 4 Canadian provinces: a population-based study","volume":"100","author":"Li","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.reumae.2024.09.002_bib1310","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574324001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574324001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T22:50:56Z","timestamp":1728600656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574324001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":262,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2173574324001114"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2024.09.002","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2024.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2024.05.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\ufffdola de Reumatolog\ufffda (SER), Colegio Mexicano de Reumatolog\ufffda (CMR) and Elsevier Espa\ufffda, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}